Abstract Library

#3290 Intratumoral serotonin might decrease the efficacy of PRRT in ileal neuroendocrine tumors

Introduction: Partial remission can be achieved by peptide receptor radionuclide therapy (PRRT) in only roughly 20% of patients with midgut neuroendocrine tumor (NET). This low remission rate can be due to the radioprotective role of stored intracytoplasmic serotonin in NET cells. If blocked, e.g. by telotristatethyl, PRRT efficacy might be increased.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Prasad V

Authors: Prasad V, Klöppel G, Lupp A, Wirtz R, Kaemmerer D,

Keywords: Ileal NET, serotonin, radioprotector, PRRT, immunohistochemistry, TPH1,

#3167 Safety of Irinotecan-based chemotherapy as second-line treatment in extrapulmonary poorly differentiated neuroendocrine carcinomas (NECs)

Introduction: Owing to their low incidence, little evidence is available on the proper treatment of Neuroendocrine Carcinomas (NECs), a subgroup of tumors with scarce prognosis. Platinum plus Etoposide have been validated as first-line therapy since the 1991, while there is no consensus regarding further-lines treatment. Irinotecan (IRI)-based chemotherapy have shown promising results in second-line setting but data on safety are poor.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Bardasi C

Authors: Bardasi C, Spallanzani A, Luppi G, Bertolini F, Fontana A,

Keywords: neuroendocrine carcinoma, Irinotecan, safety, second-line treatment, chemotherapy, NEC, adverse events,

#937 Real-World Study on Everolimus in Advanced, Progressive Neuroendocrine Tumors

Introduction: Everolimus (EVE) is a valid therapeutic option for neuroendocrine tumors (NETs). However, data in the “real-world” setting outside regulatory trials are scant.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Panzuto F, Rinzivillo M, Fazio N, De Braud F, Luppi G,

Keywords: Everolimus, compassionate use,

#490 Effect of Open-Label Everolimus After Disease Progression in Patients with Advanced Neuroendocrine Tumors: A RADIANT-2 Analysis

Introduction: In the RADIANT-2 study (NCT00412061), Everolimus + Octreotide LAR (E+O) resulted in a clinically meaningful increase in median progression-free survival (PFS; by adjudicated central review) of 5.1 months v. placebo + Octreotide LAR (P+O) in patients with advanced NET with a history of carcinoid syndrome. Investigator-assessed PFS was 12.0 months for E+O compared with 8.6 months for P+O, respectively. On radiologically confirmed disease progression, P+O patients could cross over to open-label E+O.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Hörsch D, Luppi G, Jehl V, Peeters M, Hainsworth J,

Keywords: Everolimus, Octreotide LAR, somatostatin analog, mTOR,